Your browser doesn't support javascript.
loading
Outcomes of Human Papilloma Virus Vaccination in a Private Women Health Clinic in Lebanon.
Seoud, Muhieddine; Jaafar, Iman; Ghanem, Rayan; Soubhieh, Christiane; Adra, Abdallah; Nassar, Anwar; Khalil, Ali.
Afiliación
  • Seoud M; American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.
  • Jaafar I; American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.
  • Ghanem R; American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.
  • Soubhieh C; American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.
  • Adra A; American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.
  • Nassar A; American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.
  • Khalil A; American University of Beirut Medical Center (AUBMC), Department of Obstetrics and Gynecology, Beirut, Lebanon.
Obstet Gynecol Int ; 2022: 7342061, 2022.
Article en En | MEDLINE | ID: mdl-36274656
ABSTRACT

Objectives:

The study aims to report on the feasibility and associated adverse events of HPV-Vaccination (HPVV) in a private clinic setting in Lebanon and, when available, the results of subsequent cervical cancer screening.

Methods:

Opportunistic HPV vaccination is offered at the Women's Health Center of the AUBMC. We retrospectively reviewed the patients' demographic data, the incidence of adverse events, and their cytological screening.

Results:

A cohort of healthy women (n = 1013) aged 26.2 years (12-54 years) were opportunistically vaccinated with one of two HPV vaccines; 845 (83.4%) received the quadrivalent vaccine (Q4V), and 151 (14.1%) received the bivalent vaccine (B2V). The majority (75.8%) received three doses while 16% received two doses. Out of these women, 26.3% (267) became sexually active postvaccination (NS2), whereas 17% (174) were sexually active prior to vaccination (SA) and the rest 57% (572) reported no sexual activity (NS1). Among the SA group, 26% (46/147) presented with abnormal cytology at time of vaccination. As for the NS2 women, 5% (14/267) had subsequently abnormal screening within 37 (12-103) months following vaccination.

Conclusions:

In this observational study, we report the successful introduction of HPVV with negligible adverse events. The incidence of abnormal cervical cytology was low among our patients.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Obstet Gynecol Int Año: 2022 Tipo del documento: Article País de afiliación: Líbano

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Obstet Gynecol Int Año: 2022 Tipo del documento: Article País de afiliación: Líbano
...